Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Forges Ahead With Next Round Of Multiple Myeloma Therapies

14 Dec 2023

• By Alaric DeArment

• Source: Scrip

Related Content

A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T

12 Dec 2023

Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

07 Dec 2023

BMS Speeding Six More Programs Into Late-Stage R&D

14 Sep 2023

Related Companies

Bristol Myers Squibb Company

Johnson & Johnson

2seventy Bio, Inc.

Arcellx, Inc.

Gilead Sciences, Inc.

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies ImmunoOncology Research & Development BioPharmaceutical

More from Clinical Trials

More from Conferences

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.